These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Editorial: Alpha 1-fetoprotein: need for quantitative assays.
    Author: Alpert E.
    Journal: N Engl J Med; 1974 Mar 07; 290(10):568-9. PubMed ID: 4129924.
    Abstract:
    This editorial calls for development of quantitative assays for alpha fetoprotein (AFP) which incorporate a long-overdue uniform international standard for AFP. Statistics for presently available detection techniques are reviewed; Double-gel diffusion detects serum AFP in 1/3 white hepatoma patients and 1/3 embryonal gonadal teratoblastomas. Counterimmunoelectophoresis and electroimmunodiffusion detect AFP in more than 50% of white patients with hepatoma and a higher percentage of other racial groups. Sensitive radioimmunoassays (RIAs) can detect AFP in 85-95% of hepatoma patients; the other 5-15% are considered at present not to have AFP-producing tumors. RIAs also discern AFP in 2 other conditions; 1) gastrointestinal tract tumors and entodermally derived tumors; and 2) acute viral hepatitis. AFP in newborns is usually 1-5 mg/100 ml of blood. This level decreases (half-life, 3-5 days) during neonatancy to undetectable levels. AFP is elevated in children with 3 conditions: 1) hepatocellular carcinoma of hepatoblastoma; 2) gonadal teratoblastomas or embryonal carcinoma; and 3) ataxia telangiectasia, but not in other immune deficiency diseases. During gestation, fetal serum AFP reaches a 200-400 mg/100 ml of blood peak in the first trimester which drops to less than 5 mg/100 in newborn unbilical blood. Elevated maternal serum AFP has been shown to mark fetal distress and other pregnancy complications; these amounts are measured in nanorams and require sensitivity.
    [Abstract] [Full Text] [Related] [New Search]